RankingsPricing
  1. US-listed companies
  2. ALNYLAM PHARMACEUTICALS, INC.
  3. Financials
  4. Total cash & short-term investments

ALNYLAM PHARMACEUTICALS, INC.ALNY

Market cap
$56.6B
P/E ratio
SummaryFinancials
Period EndTotal cash & short-term investments (Million USD)YoY (%)
Dec 31, 20242,689+10.62%
Dec 31, 20232,430+12.30%
Dec 31, 20222,164-8.63%
Dec 31, 20212,369+29.45%
Dec 31, 20201,830+20.21%
Dec 31, 20191,522+40.56%
Dec 31, 20181,083-35.94%
Dec 31, 20171,691+173.65%
Dec 31, 2016618-39.97%
Dec 31, 20151,029+70.92%
Dec 31, 2014602+144.89%
Dec 31, 2013246+100.20%
Dec 31, 2012123-16.11%
Dec 31, 2011146-37.20%
Dec 31, 2010233

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)